Home
Board Member Login
Advertising
Useful Links
Contact Us
Search
SEARCH AATOD
About Us
Organizational History
Overview of AATOD Activities
Patient Success Stories
Board of Directors
Member Center
Becoming an AATOD Member
Canon of Ethics
Membership Application
Membership Brochure
AATOD Conference
2018 AATOD Conference: New York City
2016 AATOD Conference: Baltimore
2015 AATOD Conference: Atlanta
2013 AATOD Conference: Philadelphia
2012 AATOD Conference : Las Vegas
2010 AATOD Conference : Chicago
2009 AATOD Conference: New York
2007 AATOD Conference: San Diego
2006 AATOD Conference: Atlanta
2004 AATOD Conference: Orlando
Photo Galleries
Projects/Educational Training
Preparing for EHRs and Healthcare reform for Opioid Treatment Providers
Hepatitis Education for Opioid Treatment Providers
Determining the Prevalence of Prescription Opioid Use among Admissions to Opioid Treatment Programs
Methadone Treatment in the Criminal Justice
PCSS-M Project (Methadone Mentoring)
Webinar Projects
Resources
Frequently Asked Questions
Glossary
Additional Education on Opioid Dependence
Publications & DVD’s
Calendar
Policies
Policy Statements
Whitepapers
End of Year Reports
AATOD Fact Sheets
Legislation
End of Year Reports
Coming Soon!
Google+
LinkedIn
Facebook
Twitter
Policies
Policy Statements
AATOD Guidelines for Guest Medication
AATOD Guidelines for Using Naltrexone (Vivitrol) in OTPs
AATOD’s Five-Year Plan
AATOD’s Response to SAMHSA’s Federal Register Notice of May 16, 2013 in Updating the Accreditation Guidelines for OTPs
Challenges and Opportunities (July 2012)
Guidance to OTPs Concerning the Use of Prescription Monitoring Program (PMP) Databases
Increasing Access to Medication to Treat Opioid Addiction – Increasing Access for the Treatment of Opioid Addiction with Medications
Medication-Assisted Treatment for Opioid Addiction: Challenges and Solutions – June 2011
Overdose Prevention
Proposal to Increase Medicaid Utilization for OTPs
Recommendations in Siting New OTPs in the United States
Washington State Prescription Monitoring Program – Notice to Patient of Evergreen Treatment Services
MAT for Opioid Addiction in the Criminal Justice System
Whitepapers
Whitepaper # 3
Improving Access to Pharmacotherapy for Opioid Use Disorder within the Criminal Justice System
Increasing Access to Medication Assisted Treatment in Drug Courts
Methods of Engaging Family Courts and Child Protective Services Through Opioid Treatment Programs and DATA 2000 Practices
End of Year Reports
AATOD Fact Sheets
Medication-Assisted Treatment for Opioid Use Disorder in the Criminal Justice System
Introduction
Evidence-Based Arguments in Support of MAT for Opioid Use Disorders
The Medications and Their Effectiveness
Myths About Medication
Policy and Legal Considerations Related to use of MAT for Opioid Use Disorder
Conclusions
References
Medication-Assisted Treatment for Opioid Use Disorders
Legislation
FOLLOW US
Days Until
AATOD 2018 Conference
2018 Conference
CLOSE
Share This
Google+
LinkedIn
Facebook
Twitter